Buspirone for the Treatment of Generalized Anxiety Disorder in Down Syndrome: 3 Cases.
J Dev Behav Pediatr
; 43(1): 38-43, 2022 01 01.
Article
em En
| MEDLINE
| ID: mdl-33965971
ABSTRACT
OBJECTIVE:
Reports on the pharmacologic treatment of anxiety, including generalized anxiety disorder (GAD), in individuals with Down syndrome (DS) are lacking.METHODS:
We present the case histories of 1 adolescent and 2 young adults with DS and the treatment course of comorbid GAD with buspirone.RESULTS:
Treatment with buspirone was safe and well-tolerated and resulted in sustained improvement in symptoms of anxiety for a minimum of 2 years in all 3 cases.CONCLUSION:
Buspirone's generally benign adverse effect profile makes it well suited for treating anxiety in individuals with DS in light of their common medical comorbidities.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Buspirona
/
Síndrome de Down
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article